Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

78.15USD
22 Apr 2019
Change (% chg)

$0.58 (+0.75%)
Prev Close
$77.57
Open
$77.59
Day's High
$79.09
Day's Low
$77.50
Volume
1,145,039
Avg. Vol
1,738,665
52-wk High
$107.24
52-wk Low
$75.77

Select another date:

Tue, Mar 19 2019

Photo

FDA puts partial hold on clinical trials of AbbVie's cancer drug

AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer drug Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the Venclexta arm of the late-stage study.

UPDATE 1-FDA puts partial hold on clinical trials of AbbVie's cancer drug

March 19 AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer drug Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the Venclexta arm of the late-stage study.

FDA puts partial hold on clinical trials of AbbVie's cancer drug

March 19 AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer treatment Venclexta for multiple myeloma.

AbbVie expects steeper decline in Humira's overseas sales; shares fall

AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent.

UPDATE 3-AbbVie expects steeper decline in Humira's overseas sales; shares fall

Jan 25 AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent.

AbbVie not contemplating big deals - CEO

Jan 25 AbbVie Inc is not considering a big merger or an acquisition, Chief Executive Officer Richard Gonzalez said on Friday, allaying speculations of the company launching a bid for Bristol-Myers Squibb.

AbbVie profit misses as Humira faces biosimilar challenge in Europe

AbbVie Inc on Friday posted a fourth-quarter profit that missed Wall Street estimates, as the drugmaker's top-selling drug, Humira, faces competition from cheaper rival versions in Europe.

AbbVie profit misses as Humira faces biosimilar challenge in Europe

Jan 25 AbbVie Inc on Friday posted a fourth-quarter profit that missed Wall Street estimates, as the drugmaker's top-selling drug, Humira, faces competition from cheaper rival versions in Europe.

AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study

AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

Select another date: